Home / Market News / $SRPT
benzinga Corporate Catalyst Impact 55/100 ● negative

JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Sep 30, 2026, 6:11 PM UTC · Primary ticker $SRPT

JP Morgan analyst Anupam Rama has reiterated a Neutral rating on Sarepta Therapeutics (SRPT) but reduced its price target from $23 to $20. This indicates a slightly more cautious outlook from the analyst, potentially due to updated financial models or market conditions for the company.

JP Morgan analyst Anupam Rama maintained a 'Neutral' rating on Sarepta Therapeutics (SRPT) but lowered the price target from $23 to $20. This action signals a slightly diminished valuation expectation for SRPT by a prominent investment bank. While the 'Neutral' rating suggests no immediate strong buy or sell recommendation, the reduced price target could exert short-term downward pressure on the stock as investors adjust their own valuation models. This primarily affects current and potential SRPT shareholders, who might see a slight erosion in perceived value. The long-term implications depend on whether other analysts follow suit or if Sarepta releases new positive data or financial results that could counteract this revised outlook. For traders, the key risk is a potential dip in share price following this news, while an opportunity might arise if the market overreacts, presenting a buying opportunity for those who believe the new target is overly conservative.

$SRPT negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.